GlassScriptPhysician profile
William Alexander Edgell
NPI 1356019319
$3,005.43
in general payments reported to CMS, 2019-2025
28 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,479 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,945 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.43 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.36 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $310.56 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $229.72 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $228.74 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $151.64 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $127.87 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $125.34 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $124.54 | 2024-2025 | |
| Irhythm Technologies, INC. | $121.10 | 2024 | Zio Xt Patch, Zio Monitor |
| Aimmune Therapeutics, INC. | $119.66 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $105.66 | 2024-2025 | Camzyos, Eliquis |
| Dexcom, INC. | $95.01 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $81.84 | 2024-2025 | Wegovy, Rybelsus |
| Organon LLC | $76.65 | 2024-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $75.62 | 2025 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $72.06 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $68.47 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbott Laboratories | $66.94 | 2024-2025 | Freestyle Libre 3 |
| Corium, LLC | $49.19 | 2024 | Azstarys |
| Inspire Medical Systems, INC. | $26.46 | 2025 | Inspire |
| Alkermes, INC. | $26.36 | 2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $24.83 | 2024 | Fanapt |
| Lundbeck LLC | $19.50 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.17 | 2025 | Xifaxan |
| Viiv Healthcare Company | $16.90 | 2024 | Apretude |
| Vertex Pharmaceuticals Incorporated | $16.09 | 2024 | |
| Janssen Pharmaceuticals, INC | $14.70 | 2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $14.45 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Edgell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.